{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:31:41Z","timestamp":1790706701445,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.hoc.2020.12.006","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T22:11:23Z","timestamp":1611612683000},"page":"375-390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Quality of Life in Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"35","author":[{"given":"Ruben","family":"Mesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Huberty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2020.12.006_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2020.12.006_bib2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"issue":"21","key":"10.1016\/j.hoc.2020.12.006_bib3","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1002\/cncr.26129","article-title":"Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial","volume":"117","author":"Mesa","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2020.12.006_bib4","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.12.006_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.leukres.2017.05.012","article-title":"Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials","volume":"59","author":"Gwaltney","year":"2017","journal-title":"Leuk Res"},{"issue":"33","key":"10.1016\/j.hoc.2020.12.006_bib6","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.12.006_bib7","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/10428194.2016.1246733","article-title":"The potential role of hematocrit control on symptom burden among polycythemia vera patients: insights from the CYTO-PV and MPN-SAF patient cohorts","volume":"58","author":"Scherber","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2020.12.006_bib8","doi-asserted-by":"crossref","first-page":"284706","DOI":"10.1155\/2015\/284706","article-title":"Impact of inflammation on myeloproliferative neoplasm symptom development","volume":"2015","author":"Geyer","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"10","key":"10.1016\/j.hoc.2020.12.006_bib9","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.12.006_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp Hematol"},{"issue":"11","key":"10.1016\/j.hoc.2020.12.006_bib11","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis","volume":"87","author":"Vaidya","year":"2012","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.hoc.2020.12.006_bib12","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2020.12.006_bib13","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1182\/blood.V122.21.4070.4070","article-title":"The relationship between cytokine levels and symptoms in patients (Pts) with myelofibrosis (MF) from COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT)","volume":"122","author":"Squires","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.12.006_bib14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.12.006_bib15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.hoc.2020.12.006_bib16","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.hoc.2020.12.006_bib17","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.006_bib18","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.12.006_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2012-01-407981","article-title":"Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early\/prefibrotic primary myelofibrosis","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.006_bib20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ejh.12707","article-title":"Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy","volume":"97","author":"Mesa","year":"2016","journal-title":"Eur J Haematol"},{"issue":"17","key":"10.1016\/j.hoc.2020.12.006_bib21","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.006_bib22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2018.09.033","article-title":"Patient perspectives regarding allogeneic bone marrow transplantation in myelofibrosis","volume":"25","author":"Palmer","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.hoc.2020.12.006_bib23","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.bbmt.2019.07.001","article-title":"Assessment of quality of life following allogeneic stem cell transplant for myelofibrosis","volume":"25","author":"Palmer","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2020.12.006_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cncr.29753","article-title":"Comprehensively understanding fatigue in patients with myeloproliferative neoplasms","volume":"122","author":"Scherber","year":"2016","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2020.12.006_bib25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/ejh.13048","article-title":"Associations between fatigue, physical activity, and QoL in patients with myeloproliferative neoplasms","volume":"100","author":"Tolstrup Larsen","year":"2018","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.hoc.2020.12.006_bib26","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.12.006_bib27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood-2019-130158","article-title":"Results from a phase 2 study of navitoclax in combination with ruxolitinib in patients with primary or secondary myelofibrosis","volume":"134","author":"Harrison","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.12.006_bib28","unstructured":"Yacoub A, Wang ES, Rampal RK, et al. Novel therapies and pitfalls in MPN. Paper presented at: European Hematology Association Annual Conference. Virtual, November 26, 2020."},{"key":"10.1016\/j.hoc.2020.12.006_bib29","first-page":"19","article-title":"Resurrecting response to ruxolitinib: a phase I study testing the combination of ruxolitinib and the PI3K delta inhibitor umbralisib in ruxolitinib-experienced myelofibrosis","volume":"2","author":"Moyo","year":"2018","journal-title":"HemaSphere"},{"issue":"3","key":"10.1016\/j.hoc.2020.12.006_bib30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/cncr.30325","article-title":"Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: findings from the MPN Landmark survey","volume":"123","author":"Mesa","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2020.12.006_bib31","author":"Network"},{"issue":"10","key":"10.1016\/j.hoc.2020.12.006_bib32","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.3324\/haematol.2017.168583","article-title":"Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms","volume":"102","author":"Huberty","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.hoc.2020.12.006_bib33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.amepre.2009.02.002","article-title":"How we design feasibility studies","volume":"36","author":"Bowen","year":"2009","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.hoc.2020.12.006_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12906-019-2530-8","article-title":"Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research","volume":"19","author":"Huberty","year":"2019","journal-title":"BMC Complement Altern Med"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.006_bib35","doi-asserted-by":"crossref","first-page":"e12662","DOI":"10.2196\/12662","article-title":"Smartphone-based meditation for myeloproliferative neoplasm patients: feasibility study to inform future trials","volume":"3","author":"Huberty","year":"2019","journal-title":"JMIR Form Res"},{"issue":"4","key":"10.1016\/j.hoc.2020.12.006_bib36","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1177\/1534735418808595","article-title":"Perceptions of myeloproliferative neoplasm patients participating in an online yoga intervention: a qualitative study","volume":"17","author":"Huberty","year":"2018","journal-title":"Integr Cancer Ther"},{"issue":"2","key":"10.1016\/j.hoc.2020.12.006_bib37","doi-asserted-by":"crossref","first-page":"e14292","DOI":"10.2196\/14292","article-title":"Experiences of using a consumer-based mobile meditation app to improve fatigue in myeloproliferative patients: qualitative study","volume":"5","author":"Huberty","year":"2019","journal-title":"JMIR Cancer"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882030157X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882030157X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:17:38Z","timestamp":1760185058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985882030157X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S088985882030157X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.12.006","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of Life in Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}